Vectura’s portfolio has emerged from the Company’s product development, formulation and drug delivery expertise and is currently centred around developing inhaled products to address unmet needs in airways diseases.

We continue to focus on balancing the unmet needs of all stakeholders (patients, physicians, payors) with commercial attractiveness and exploiting valuable niches in our therapeutic space.

Vectura Group plc Recommended All Share Merger with Skyepharma PLC

   Investors

Date: 29/04/2016

Share price summary

1

WE INNOVATE

2

WE DEVELOP

3

WE COLLABORATE

Annual report

AR-15.png

Download annual report

Presentations and webcasts

09 June 2016

Jefferies 2016 Healthcare Conference, New York

21-22 June 2016

Citi EU Healthcare Conference, London

23 June 2016

J.P. Morgan Healthcare Conference, London